Search Results
Mar 18, 2026, 08:50 ET Riverside-Backed Vomela Appoints Brian Hazelton as CEO Following Year of Strategic Growth
retail graphics, complex structures, and custom installations for innovative brand experiences with operations in North America and Europe, and PFL, a tech-enabled direct mail automation company.In 2025, the company also launched an Ownership Works program for its more than 2,100
More news about: Vomela
Jan 10, 2026, 06:19 ET Pierre Fabre Laboratories e Iktos annunciano una collaborazione integrata per la scoperta di farmaci in oncologia basata sull'IA
pipeline R&S. Sono in fase di sviluppo PFL-241 e PFL-721, due inibitori selettivi dell'EGFR mutante per il trattamento dei pazienti affetti da carcinoma polmonare non a piccole cellule (NSCLC) indotto dall'EGFR. È in fase di sperimentazione clinica PFL-002 su tumori solidi causati da alterazioni
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 10:58 ET Pierre Fabre LaboratoriesとIktos、腫瘍学分野におけるAI駆動型統合新薬探索の共同プロジェクトを発表
LaboratoriesのR&Dパイプラインについて：Pierre Fabre Laboratoriesは、R&Dパイプラインに複数の資産を追加することで、精密腫瘍学への取り組みを拡大しています。PFL-241およびPFL-721の2つの変異型選択的EGFR阻害剤は、EGFR駆動型非小細胞肺がん（NSCLC）患者の治療を目的に開発されています。PFL-002は、MET遺伝子変異により駆動される固形腫瘍を対象に臨床試験が進行中です。汎RAF阻害剤であるエクサラフェニブは、RAS/RAF駆動型固形腫瘍に対する標的療法の選択肢を拡大するために開発されています。さらに、さまざまな腫瘍学ターゲットに対する前臨床候補は、Vernalis
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 10:54 ET Pierre Fabre Laboratories und Iktos kündigen eine integrierte KI-gestützte Zusammenarbeit bei der Arzneimittelentdeckung in der Onkologie an
und Entwicklungspipeline um mehrere Produkte erweitert. PFL-241 und PFL-721, zwei mutantenselektive EGFR-Inhibitoren, werden für die Behandlung von Patienten mit nicht-kleinzelligem Lungenkrebs (NSCLC) entwickelt, der durch EGFR verursacht wird. PFL-002 befindet sich in der klinischen Erprobung bei soliden
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 06:08 ET Pierre Fabre Laboratories e Iktos se unen en el descubrimiento de fármacos en oncología basada en IA
precisión incorporando varios activos a su cartera de I+D. PFL-241 y PFL-721, dos inhibidores del EGFR selectivos de mutantes, se están desarrollando para el tratamiento de pacientes con cáncer de pulmón de células no pequeñas (CPCNP) inducido por EGFR. PFL-002 se encuentra en fase de pruebas clínicas en tumores
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 02:00 ET Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology
in precision oncology by adding several assets to its R&D pipeline. PFL-241 and PFL-721, two mutant-selective EGFR inhibitors, are being developed for the treatment of EGFR-driven non-small cell lung cancer (NSCLC) patients. PFL-002 is undergoing clinical testing in solid tumors driven by MET genetic
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 02:00 ET Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology
in precision oncology by adding several assets to its R&D pipeline. PFL-241 and PFL-721, two mutant-selective EGFR inhibitors, are being developed for the treatment of EGFR-driven non-small cell lung cancer (NSCLC) patients. PFL-002 is undergoing clinical testing in solid tumors driven by MET genetic
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 02:00 ET Les Laboratoires Pierre Fabre et Iktos annoncent une collaboration basée sur l'intelligence artificielle intégrée dans le domaine de la recherche de médicaments contre le cancer
actifs à leur pipeline de R&D. Le PFL-241/STX-241 et le PFL-721/STX-721, deux inhibiteurs mutants sélectifs de l'EGFR, seront développés pour le traitement des patients atteints de cancer du poumon non à petites cellules (CPNPC) dû à une mutation de l'EGFR. Le PFL-002/VERT-002 fera l'objet d'essais
More news about: Pierre Fabre Laboratories
Nov 13, 2025, 11:00 ET VICE SPORTS TEAMS WITH NATIONAL HOT ROD ASSOCIATION FOR "CHASING SPEED"
partnership continues VICE TV's expansion into live and unscripted sports storytelling. VICE TV recently announced a deal with Professional Fighters League (PFL), the global powerhouse in MMA and fastest-growing sports league worldwide, to serve as the exclusive linear US telecast home for ten international events,
More news about: National Hot Rod Association (NHRA)
Aug 07, 2025, 08:46 ET VOW Closes Seed Round led by KB Partners to Revolutionize Live Events and Premium Experiences with AI
guest coordination into one seamless and intelligent solution. VOW is already trusted by iconic brands, including NBC's Saturday Night Live, PFL-MMA, and GLAAD Media. In the future, event professionals will be supported by a digital event team in the cloud and, guests, a real-time concierge, all
More news about: VOW
Jul 10, 2025, 09:00 ET PROFESSIONAL FIGHTERS LEAGUE NAMES JOHN MARTIN AS CHIEF EXECUTIVE OFFICER
Fighters League (PFL) is a global powerhouse in MMA and the fastest-growing sports league world-wide. PFL is the only MMA organization with the "win and advance" tournament format. PFL has three fight products: PFL World Tournament, PFL Champions Series, and PFL International Leagues. PFL is broadcast and
More news about: Professional Fighters League (PFL)
Jul 09, 2025, 10:00 ET The Vomela Companies Acquires Leading Direct Mail Automation and Printing Company PFL to Expand Its Capabilities
engagement. Advisors Citizens Capital Markets & Advisory served as the exclusive financial advisor to PFL and Goodwin served as legal counsel to PFL. About The Vomela Companies The Vomela Companies, headquartered in St. Paul, Minnesota,
More news about: The Vomela Companies
Jun 16, 2025, 04:00 ET Les Laboratoires Pierre Fabre consolident leur portefeuille R&D et annoncent l'acquisition des droits monde pour PFL-721 et PFL-241
Pierre Fabre détiennent désormais les droits monde pour toutes les molécules de notre portefeuille R&D : exarafenib, PFL-002 (anciennement VERT-002), PFL-721 et PFL-241. L'équipe R&D est pleinement engagée pour faire avancer le développement clinique de ces programmes, dans
More news about: Pierre Fabre Laboratories
Jun 16, 2025, 04:00 ET Pierre Fabre Laboratories stärken ihr F&E-Portfolio und geben den Erwerb der weltweiten Rechte für PFL-721 und PFL-241 bekannt
besitzen die Pierre Fabre Laboratories nun die weltweiten Rechte für alle Vermögenswerte in unserem R&D-Portfolio: Exarafenib, PFL-002 (früher VERT-002), PFL-721 und PFL-241. Das R&D-Team arbeitet mit vollem Engagement daran, die klinische Entwicklung dieser Programme voranzutreiben, um neuartige
More news about: Pierre Fabre Laboratories
Jun 16, 2025, 04:00 ET Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
with Antares, Pierre Fabre Laboratories now own the global rights for all the assets within our R&D portfolio: exarafenib, PFL-002 (formerly VERT-002), PFL-721 and PFL-241. The R&D team is fully engaged and committed to progress the clinical development of these programs, aiming at providing novel
More news about: Pierre Fabre Laboratories
Jun 16, 2025, 04:00 ET Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
with Antares, Pierre Fabre Laboratories now own the global rights for all the assets within our R&D portfolio: exarafenib, PFL-002 (formerly VERT-002), PFL-721 and PFL-241. The R&D team is fully engaged and committed to progress the clinical development of these programs, aiming at providing novel
More news about: Pierre Fabre Laboratories
Jun 16, 2025, 04:00 ET Pierre Fabre Laboratoriesが研究開発ポートフォリオを強化し、PFL-721およびPFL-241の全世界における権利の取得を発表
PFL-721は変異特異的なEGFRエクソン20およびHER2エクソン20阻害剤であり、まもなくNSCLCにおけるヒト初回試験内で用量最適化段階に移行する予定です。PFL-241は、変異特異的、脳浸透性の第4世代EGFR阻害剤であり、現在、NSCLC患者のC797S耐性変異に対処するために、ヒト初の臨床試験で用量漸増中です。 NSCLCは肺がんの最も一般的なサブタイプです。さまざまなEGFR変異がNSCLCの最も頻度の高いドライバーであり、地域にもよりますが、腫瘍の約14～38パーセントに認められます。[1],
More news about: Pierre Fabre Laboratories
Jun 16, 2025, 04:00 ET Los Laboratorios Pierre Fabre refuerzan su cartera de I+D
Los Laboratorios Pierre Fabre refuerzan su cartera de I+D y anuncian la adquisición de los derechos mundiales de PFL-721 y PFL-241 PFL-721 y PFL-241 son inhibidores de EGFR específicos de mutantes con un potencial excepcional, y se están desarrollando como opciones de tratamiento
More news about: Pierre Fabre Laboratories
Jun 16, 2025, 04:00 ET Pierre Fabre Laboratories rafforza il portafoglio R&D e annuncia l'acquisizione dei diritti mondiali per PFL-721 e PFL-241
Antares, Pierre Fabre Laboratories ora possiedono i diritti globali su tutti gli asset del nostro portafoglio R&D: exarafenib, PFL-002 (in precedenza VERT-002), PFL-721 e PFL-241. Il team di ricerca e sviluppo è pienamente impegnato e determinato a far progredire lo sviluppo clinico di questi programmi,
More news about: Pierre Fabre Laboratories
Jun 08, 2025, 16:40 ET Monster Energy's Merab Dvalishvili Defeats Sean O'Malley to Defend UFC Bantamweight Title at UFC 316 in Newark
version of me." Before making her UFC debut in January 2024, Harrison was the Women's Lightweight Champion in the PFL promotion in 2019 and 2021. Harrison is also the 2012 and 2016 Olympic gold medalist in judo. Right after claiming the belt, Harrison called former
More news about: Monster Energy
Jun 05, 2025, 11:00 ET PFL LAUNCHES NEW FREE CONSUMER APP - EXCLUSIVE US HOME FOR PFL INTERNATIONAL LEAGUE LIVE FIGHTS
the free vehicle for Americans to watch all PFL International League events and fights live, including PFL Europe, PFL MENA, and PFL Africa. Globally, the new PFL App is a comprehensive home for PFL information, entertainment and engagement, including PFL fights and fighter information, advanced analytics,
More news about: Professional Fighters League (PFL)
May 21, 2025, 09:00 ET PFL Partners With RHEI to Power a New Era of Combat Sports Fandom
LEAGUEProfessional Fighters League (PFL) is a global powerhouse in MMA and the fastest-growing sports league world-wide. PFL is the only MMA organization with the "win and advance" format. PFL is broadcast and streamed to 190 countries with 20 leading media partners. PFL is backed by major blue-chip investors
More news about: RHEI Creations Corp
May 19, 2025, 13:46 ET Global Investment Giant IFC (World Bank) Invests in VUZ $12M Pre-Series C, the World's Leading Immersive Media Company
views to date; targeting over 5 billion by 2026Exclusive immersive content partnerships with LaLiga, Serie A, PFL, and moreThe largest exclusively owned immersive premium content library of over 30,000 hoursOver 40
More news about: VUZ
May 19, 2025, 13:38 ET Global Investment Giant IFC (World Bank) Invests in VUZ $12M Pre-Series C, the World's Leading Immersive Media Company
views to date; targeting over 5 billion by 2026Exclusive immersive content partnerships with LaLiga, Serie A, PFL, and moreThe largest exclusively owned immersive premium content library of over 30,000 hoursOver 40
More news about: VUZ
May 19, 2025, 13:38 ET Global Investment Giant IFC (World Bank) Invests in VUZ $12M Pre-Series C, the World's Leading Immersive Media Company
views to date; targeting over 5 billion by 2026Exclusive immersive content partnerships with LaLiga, Serie A, PFL, and moreThe largest exclusively owned immersive premium content library of over 30,000 hoursOver 40
More news about: VUZ